Back to today’s briefing

Story perspectives

Stockholm3 Detects 90% Aggressive Prostate Cancers, Outperforms PSA

6/28/2026

38 8 Full Breakdown

Summary

Story summary

Stockholm3 identified 90% of aggressive prostate cancers, surpassing PSA’s 74% detection.
The trial enrolled 12,000 men aged 50-74 and followed them for years, yielding 443 cancer cases.
Stockholm3’s higher detection could reduce unnecessary MRIs and biopsies, while false-positive rates matched PSA.
A3P Biomedical plans to seek FDA approval because the test is not yet sold in the United States.

1 of 1

Story summary

Stockholm3 identified 90% of aggressive prostate cancers, surpassing PSA’s 74% detection.
The trial enrolled 12,000 men aged 50-74 and followed them for years, yielding 443 cancer cases.
Stockholm3’s higher detection could reduce unnecessary MRIs and biopsies, while false-positive rates matched PSA.
A3P Biomedical plans to seek FDA approval because the test is not yet sold in the United States.